Affinity tag nucleic acid and protein compositions, and processes for using same -> Monitor Keywords

Site News |

Monitor Keywords |

Monitor Archive |

Organizer |

Account Info |

06/25/09 - USPTO Class 435 | 1 views | #20090162845 | Prev - Next | About this Page

Affinity tag nucleic acid and protein compositions, and processes for using same

Title: Affinity tag nucleic acid and protein compositions, and processes for using same

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20090162845, Affinity tag nucleic acid and protein compositions, and processes for using same.

What is claimed is:

1. A composition which comprises a nucleic acid and one member of an affinity binding pair, wherein said member is attached to one or more nucleotides of said nucleic acid through a phosphate or sugar of said nucleotide or nucleotides.

2. The composition of claim 1, wherein said affinity binding pair comprises: (a) a metal binding peptide and an immobilized metal, or (b) a peptide affinity group.

3. The composition of claim 2, wherein said metal binding peptide comprises any of the amino acid sequences: oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

4. The composition of claim 2, wherein said immobilized metal comprises nickel, copper, cobalt or zinc.

5. The composition of claim 2, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

6. The composition of claim 1, wherein said member is attached to said nucleotide or nucleotides through a linker arm.

7. The composition of claim 1, further comprising one or more energy transfer donors.

8. The composition of claim 1, further comprising one or more energy transfer acceptors.

9. A chimeric nucleic acid comprising at least two portions, a first portion comprising a nucleic acid complementary to a nucleic acid sequence of interest, and a second portion comprising a metal binding peptide, wherein said metal binding peptide is attached to one or more nucleotides of the nucleic acid in said first portion through a sugar or phosphate of said nucleotide or nucleotides.

10. The composition of claim 9, wherein said metal binding peptide comprises any of the amino acid sequences: oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

11. The composition of claim 9, wherein said metal or metals are attached to said nucleotide or nucleotides through a linker arm.

12. The composition of claim 9, wherein said metal binding peptide has an affinity for nickel, copper, cobalt or zinc.

13. The composition of claim 9, further comprising one or more energy transfer donors.

14. The composition of claim 9, further comprising one or more energy transfer acceptors.

15. A chimeric nucleic acid comprising at least two portions, a first portion comprising a nucleic acid complementary to a nucleic acid sequence of interest, and a second portion comprising one member of a peptide affinity group, wherein said member is attached to one or more nucleotides of said nucleic acid in said first portion.

16. The chimeric nucleic acid of claim 15, wherein said peptide affinity binding group comprises any of the pairs: S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

17. The composition of claim 15, wherein said member is attached to said nucleotide or nucleotides through a linker arm.

18. The composition of claim 15, further comprising one or more energy transfer donors.

19. The composition of claim 15, further comprising one or more energy transfer acceptors.

20. A process for isolating one or more species of a nucleic acid of interest, comprising the steps of: providing: a sample containing or suspected of containing said nucleic acid of interest, a composition which comprises a nucleic acid portion and a first member of an affinity binding pair, wherein said nucleic acid portion comprises sequences complementary to said nucleic acid species of interest, wherein said affinity binding pair comprises (a) a metal binding peptide and an immobilized metal, or (b) a peptide affinity group; and wherein said first member of the affinity binding pair is attached to one or more nucleotides in said nucleic acid portion; and a matrix comprising a second member of said affinity binding pair; hybridizing said composition with any nucleic acid of interest contained in said sample to form a first complex; contacting said first complex with said matrix to form a second complex by means of a binding interaction between said first member and said second member of the affinity binding pair; and separating bound from unbound material, thereby isolating said nucleic acid species of interest.

21. The process of claim 20, wherein said metal binding peptide comprises any of the amino acid sequences: oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7). KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

22. The process of claim 20, wherein said immobilized metal comprises nickel, copper, cobalt or zinc.

23. The process of claim 20, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

24. The process of claim 20, wherein said first member of said affinity binding pair is attached to said one or more nucleotides through a linker arm.

25. The process of claim 20, wherein in said separating step the portion of said sample that remains unbound to said matrix comprises said nucleic acid species of interest.

26. The process of claim 20, wherein the portion of said sample that remains bound to said matrix comprises said nucleic acid species of interest.

27. The process of claim 20, further comprising one or more washing steps.

28. A process for detecting the presence or quantity of a nucleic acid of interest, comprising the steps of: providing: a sample containing labeled nucleic acids, a composition comprising a nucleic acid portion and a first member of an affinity binding pair, wherein said nucleic acid portion comprises sequences complementary to said nucleic acid of interest, and a matrix comprising a second member of said affinity binding pair; wherein said affinity binding pair comprises (a) a metal binding peptide and an immobilized metal, or (b) a peptide affinity group; and wherein said first member of the affinity binding pair is attached to one or more nucleotides of said nucleic acid portion; and hybridizing said composition with any nucleic acid of interest contained in said sample to form a first complex; contacting said first complex with said matrix to form a second complex by means of a binding interaction between said first member and said second member of said affinity binding pair; and washing said matrix to remove unhybridized nucleic acids from said matrix; and detecting or quantifying said nucleic acid of interest by means of detecting or quantifying a signal from said labels.

29. The process of claim 28, wherein said metal binding peptide comprises any of the amino acid sequences: oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

30. The process of claim 28, wherein said immobilized metal comprises nickel, copper, cobalt or zinc.

31. The process of claim 28, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

32. The process of claim 28, wherein said first member of the affinity binding pair is attached to said nucleotide or nucleotides through a linker arm.

33. The process of claim 28, wherein said labeled nucleic acids in the sample comprise one or more energy transfer donors and wherein said composition comprise one or more energy transfer acceptors.

34. The process of claim 28, wherein said labeled nucleic acids in the sample comprise one or more energy transfer acceptors and wherein said composition comprise one or more energy transfer donors.

35. The process of claim 28, wherein said labeled nucleic acids comprise labels that are fluorescently, chemiluminescently, colorimetrically or enzymatically detectable.

36. The process of claim 28, further comprising a step of releasing said second complex from said matrix prior to said detecting step.

37. A process for detecting the presence or quantity of a nucleic acid of interest, comprising the steps of: providing: a sample containing or suspected of containing said nucleic acid of interest; a labeled probe complementary to said nucleic acid of interest; a composition comprising a nucleic acid portion and a first member of an affinity binding pair, wherein said nucleic acid portion comprises sequences complementary to said nucleic acid of interest, wherein said affinity binding pair comprises (a) a metal binding peptide and an immobilized metal, or (b) a peptide affinity group, and wherein said first member of the affinity binding pair is attached to one or more nucleotides of said nucleic acid portion through a sugar, phosphate or base of said nucleotide or nucleotides; and a matrix comprising a second member of said affinity binding pair; hybridizing any nucleic acids of interest in said sample with labeled probe and said composition to form a first complex; contacting said first complex with said matrix to form a second complex by means of a binding interaction between said first member and said second member of said affinity binding pair; washing said matrix to remove unbound materials from said sample; and detecting or quantifying said nucleic acid of interest by means of detecting or quantifying a signal from said labels.

38. The process of claim 37, wherein said metal binding peptide (a) comprises any of the amino acid sequences: oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

39. The process of claim 37, wherein said immobilized metal comprises nickel, copper, cobalt or zinc.

40. The process of claim 37, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

41. The process of claim 37, wherein said first member of the affinity binding pair is attached to said nucleotide or nucleotides through a linker arm.

42. The process of claim 37, wherein said labeled probes comprise one or more energy transfer donors and wherein said composition comprises one or more energy transfer acceptors.

43. The process of claim 37, wherein said labeled probes comprise one or more energy transfer acceptors and wherein said composition comprises one or more energy transfer donors.

44. The process of claim 37, wherein said labeled probes comprise one or more energy transfer donors and wherein the nucleic acids in said sample have been labeled with one or more energy transfer acceptors.

45. The process of claim 37, wherein said labeled probes comprise one or more energy transfer acceptors and wherein the nucleic acids in said sample have been labeled with one or more energy transfer donors.

46. The process of claim 37, wherein said labeled nucleic acids are detected fluorescently, chemiluminescently, colorimetrically or enzymatically.

47. The process of claim 37, further comprising a step of releasing said second complex from said matrix prior to said detecting step.

48. A process for detecting the presence or quantity of a nucleic acid of interest, comprising the steps of: providing: a sample containing or suspected of containing said nucleic acid of interest; a probe complementary to said nucleic acid of interest and comprising two portions, wherein a first comprises sequences complementary to said nucleic acid of interest, and a second portion comprising a signal sequence; a composition comprising a nucleic acid portion and a first member of an affinity binding pair, wherein said nucleic acid portion comprises sequences complementary to said nucleic acid of interest, wherein said affinity binding pair comprises (a) a metal binding peptide and an immobilized metal, or (b) a peptide affinity group, and wherein said first member of the affinity binding pair is attached to one or more nucleotides of said nucleic acid; and a matrix comprising a second member of said affinity binding pair; hybridizing any nucleic acids of interest in said sample with labeled probe and said composition to form a first complex; contacting said first complex with said matrix to form a second complex by means of a binding interaction between said one or more binding partners and said affinity peptide; washing said matrix to remove unbound materials from said sample; and detecting or quantifying said nucleic acid of interest by hybridizing labeled oligonucleotides complementary to said signal sequence.

49. The process of claim 48, wherein said metal binding peptide comprises any of the amino acid sequences oligohistidine, HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

50. The process of claim 48, wherein said immobilized metal comprises nickel, copper, cobalt or zinc.

51. The process of claim 48, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

52. The process of claim 48, wherein said labeled oligonucleotides are detected fluorescently, chemiluminescently, colorimetrically or enzymatically.

53. The process of claim 48, wherein said signal sequence comprises a homopolymeric sequence.

54. The process of

48, wherein said signal sequence comprises a heterologous sequence, wherein said heterologous sequence is neither identical or complementary to said nucleic acid of interest.

55. A fusion protein comprising a biologically active polypeptide or protein and at least one affinity peptide attached to the amino-terminus or the carboxyl-terminus of said biologically active polypeptide or protein, wherein said affinity peptide comprises at least a portion of the amino acid sequence of kininogen, said portion comprising a metal binding peptide.

56. A fusion protein comprising a biologically active polypeptide or protein and an affinity peptide attached at the amino-terminus and an affinity peptide attached at the carboxyl-terminus of said biologically active polypeptide or protein, wherein said affinity peptides comprise at least a portion of the amino acid sequence kininogen, said portion comprising a metal binding peptide.

57. The fusion protein of claim 55 or 56, wherein said affinity peptide comprises the sequence GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10), or a portion thereof.

58. The fusion protein of claim 55 or 56, wherein said kininogen comprises human kininogen.

59. The fusion protein of claim 55 or 56, wherein said fusion protein comprises an amino acid sequence between said biologically active polypeptide or protein and said affinity peptides, wherein said sequence is recognizable by a protease.

60. The fusion protein of claim 59, wherein said protease comprises enterokinase or coagulation factor Xa.

61. The fusion protein of claim 55, wherein said affinity peptide binds nickel, copper, cobalt or zinc.

62. A fusion protein comprising an antibody linked by its amino- and/or carboxyl-terminus to one or two affinity peptides, wherein said affinity peptide binds to a metal, and wherein said antibody has an affinity to an epitope on a different antibody.

63. The fusion protein of claim 62, wherein said affinity peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

64. A process for modifying a protein of interest, said process comprising the steps of: providing (i) a nucleic acid that codes for said protein of interest; (ii) a nucleic acid that codes for a portion of the amino acid sequence of kininogen, wherein said portion codes for a metal binding peptide; and (iii) an expression vector; adding said nucleic acid (ii) to said nucleic acid (i) to generate a nucleic acid coding for a fusion protein; and inserting said nucleic acid coding for said fusion protein into said expression vector (iii), thereby generating a vector that expresses said modified protein of interest.

65. The process of claim 64, wherein said expression vector (iii) comprises a mammalian expression vector, a bacterial expression vector, an insect cell expression vector and a yeast expression vector.

66. The process of claim 64, wherein said expression vector (iii) comprises a plasmid or viral vector.

67. A process for isolating a protein of interest, said process comprising the steps of: providing: (i) a nucleic acid that codes for said protein of interest; (ii) a nucleic acid that codes for a portion of the amino acid sequence of kininogen, wherein said portion codes for a metal binding peptide; (iii) an expression vector; and (iv) a metal-modified matrix; adding said nucleic acid (ii) to said nucleic acid (i) to generate a nucleic acid coding for a fusion protein; inserting said nucleic acid coding for said fusion protein into said expression vector (iii), thereby generating a vector that expresses said protein of interest; and purifying said modified protein of interest by binding said protein of interest to said metal-modified matrix (iv).

68. The process of claim 67, wherein said expression vector (iii) comprises a mammalian expression vector, a bacterial expression vector, an insect cell expression vector and a yeast expression vector.

69. The process of claim 67, wherein said expression vector (iii) comprises a plasmid or viral vector.

70. The process of claim 67, wherein said purifying step, the metal-modified matrix comprises a chromatographic column or a microtitre plate.

71. A fusion protein comprising an antibody and at least one affinity peptide attached to the amino terminus or the carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody.

72. A fusion protein comprising an antibody and an affinity peptide attached to the amino terminus and an affinity peptide attached to carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody.

73. The fusion protein of claim 71, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

73. The fusion protein of claim 62, wherein said metal binding peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO: 1, SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

74. A process for isolating an analyte of interest, said process comprising the steps of: providing (i) a sample containing or suspected of containing said analyte of interest; (ii) a first antibody having an affinity for said analyte; (iii) a fusion antibody comprising: (a) an antibody and at least one affinity peptide attached to the amino terminus or the carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; or (b) an antibody and an affinity peptide attached to the amino terminus and an affinity peptide attached to carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; and (iv) a matrix comprising a metal or a second member of said affinity peptide group. contacting said sample with said first antibody, thereby forming a first complex between said first antibody and any analyte present in said sample; contacting said first complex with said fusion antibody, thereby forming a second complex between said first complex and said fusion antibody; contacting said second complex with said matrix to bind said second complex to said matrix; removing unbound material from said matrix, and releasing said analyte of interest from said second complex, thereby isolating said analyte of interest.

75. The process of claim 74, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

76. The process of claim 74, wherein said metal binding peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

77. A process for detecting or quantifying an analyte of interest, said process comprising the steps of: providing (i) a labeled sample containing or suspected of containing labeled analyte of interest; (ii) a first antibody having an affinity for said analyte; (iii) a fusion antibody comprising: (a) an antibody and at least one affinity peptide attached to the amino terminus or the carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; or (b) an antibody and an affinity peptide attached to the amino terminus and an affinity peptide attached to carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; and (iv) a matrix comprising a metal or a second member of said affinity peptide group; contacting said sample with said first antibody, thereby forming a first complex between said first antibody and any analyte present in said sample; contacting said first complex with said fusion antibody, thereby forming a second complex between said first complex and said fusion antibody; contacting said second complex with said matrix to bind said second complex to said matrix; removing unbound material from said matrix; and detecting or quantifying said labeled analytes bound to said matrix by means of detecting or quantifying a signal from said labels.

78. The process of claim 77, wherein said peptide affinity group comprises S-protein and S-peptide, GST and GSH, PKA peptide and PKA, HA peptide and HA, KSI and oligo PHE, KSI and oligo Leu, oligo Arg and oligo Glu, or oligo Arg and oligo Asp.

79. The process of claim 77, wherein said metal binding peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO: 1), SPHHG (SEQ ID NO: 2), SPHHGGSPHHG (SEQ ID NO: 3), HPHHG (SEQ ID NO: 4), HPHHGGHPHHG (SEQ ID NO: 5), SPHHGGHPHHG (SEQ ID NO: 6), HPHHGGSPHHG (SEQ ID NO: 7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO: 8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO: 10) or HGLGHGHEQQHGLGHGH (SEQ ID NO: 9).

80. The process of claim 77, wherein said analyte of interest comprises a protein or polypeptide.

81. The process of claim 77, further comprising the step of releasing said analyte of interest from said second complex prior to said detecting or quantifying step.

82. The process of claim 77, wherein said labeled analytes are detected fluorescently, chemiluminescently, colorimetrically or enzymatically.

83. A process for detecting or quantifying an analyte of interest, said process comprising the steps of: providing (i) a labeled sample containing or suspected of containing labeled analytes of interest; (ii) a first antibody having an affinity for said analyte; (iii) a fusion antibody comprising: (a) an antibody and at least one affinity peptide attached to the amino terminus or the carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; or (b) an antibody and an affinity peptide attached to the amino terminus and an affinity peptide attached to carboxyl terminus of said antibody, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group, wherein said antibody has an affinity for a different antibody; and (iv) a matrix comprising a metal or a second member of said affinity peptide group. forming a first complex among said matrix, said fusion antibody and said first antibody; contacting said first complex with said labeled sample, thereby forming a second complex between said first complex and any labeled analytes that may be present in said sample; removing unbound material from said matrix; and detecting or quantifying said labeled analytes bound to said matrix by means of detecting or quantifying a signal from said labels.

84. The process of claim 83, wherein said matrix comprises an array of different first antibodies, thereby detecting or quantifying multiple analytes of interest.

85. The process of claim 83, wherein said labeled analytes are detected fluorescently, chemiluminescently, colorimetrically or enzymatically.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Affinity tag nucleic acid and protein compositions, and processes for using same patent application.

Patent Applications in related categories:

20090291445 - Biomarker of lung injury and repair - The present invention resides in the discovery that circulating cytokaretin 5 (CK5) mRNA level correlates with the presence of a lung injury or disease as well as the severity or stage of the injury or disease. Diagnostic methods and kits are provided. ...

20090291450 - Caterpiller gene family - The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural motifs including a nucleotide binding domain and leucine-rich repeat domains. ...

20090291431 - Compositions and methods to detect legionella pneumophila nucleic acid - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for Legionella pneumophila 16S or 23S rRNA sequences or DNA encoding 16S or 23S rRNA. Methods are disclosed for detecting the presence of L. pnuemophila ...

20090291433 - Droplet-based nucleic acid amplification method and apparatus - The present invention relates to a droplet-based nucleic acid amplification method and apparatus. According to one embodiment, a method of amplifying a nucleic acid in a biological sample is provided, wherein the method includes: (a) providing a system comprising a droplet microactuator electronically coupled to and controlled by a processor ...

20090291434 - Gene expression markers for colorectal cancer prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. ...

20090291432 - Genetic profiles associated with the 957c>t polymorphism in the drd2 gene - The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the ...

20090291442 - Hspa1a as a marker for sensitivity to ksp inhibitors - The present invention relates to methods for predicting a response to treatment with a kinesin spindle protein inhibitor using heat shock protein 70, isoform A1a, also known as HSPA1a, as a marker for sensitivity to the kinesin spindle protein (KSP) inhibitors. Method are provided for predicting a response to treatment ...

20090291449 - Method and apparatus to minimize diagnostic and other errors due to transposition of biological specimens among subjects - A method and apparatus for minimizing diagnostic errors due to transposition of biological specimens among subjects provides for independent biometric confirmation that a given specimen is from a given donor. In certain embodiments, a biological specimen confirmation kit comprises a portable and openable case housing components of the kit, at ...

20090291446 - Method for confirming the presence of an analyte - The invention provides methods and kits for the rapid confirmation of an initial analyte test result. In a preferred embodiment, the process confirms the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related ...

20090291440 - Method for synthesizing nucleic acid using dna polymerase beta and single molecule sequencing method - The present invention provides a nucleic acid synthesis method capable of continuously carrying out an extension reaction and a single molecule sequencing method capable of obtaining base information accurately at high speed. A method for synthesizing a nucleic acid, including the steps of: forming a complex of a target nucleic ...

20090291447 - Method of detecting colon cancer marker - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting ...

20090291444 - Methods and materials for detecting and treating dementia - This document relates to methods and materials involved in detecting mutations linked to dementia (e.g., frontotemporal lobar degeneration). For example, methods and materials for determining whether or not a mammal is homozygous for a mutant T allele of rs5848 are provided. This document also relates to methods and materials involved ...

20090291451 - Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome - The present invention provides assays and kits for diagnosing idiopathic congenital central hypoventilation syndrome. The present assays and kits focus on the second polyalanine repeat of the PHOX2b gene or gene product, which is normally 20 residues in length. A polyalanine repeat 25 to 33 residues in length is strongly ...

20090291438 - Methods for analysis of extracelluar rna species - The invention provides methods and kits for enabling quantitative or qualitative analysis of extracellular RNA species in non-cellular bodily fluids including plasma and serum to detect, infer, evaluate, or monitor cancer and other neoplasia or other diseases of interest. ...

20090291436 - Methods for detecting nucleic acids indicative of cancer - The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer. ...

20090291437 - Methods for targeting quadruplex sequences - Provided are quadruplex nucleotide sequences and methods for identifying interacting molecules. ...

20090291452 - Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy - A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel ...

20090291439 - Phosphatases involved in the regulation of cardiomyocyte differentiation - (C) an amino acid sequence having at least 60% or more homology to the amino acid sequence of SEQ ID NO:2 and having cysteine at position 138, wherein a protein consisting of the amino acid sequence has a dual specificity phosphatase activity. (B) an amino acid sequence wherein one or several ...

20090291441 - Polypeptide, nucleic acid molecule encoding it and their uses - A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions ...

20090291448 - Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. ...

20090291435 - Thermal reaction device and method for using the same - Devices and methods for performing the relative concentration of a target in a sample, the sample containing both target and non-target components, the method performed by partitioning the sample into a large number of reaction volumes such that the target is concentrated relative to the non-target, and performing a detection ...

20090291443 - Use of highly parallel snp genotyping for fetal diagnosis - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. ...

###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Affinity tag nucleic acid and protein compositions, and processes for using same or other areas of interest.
###

Previous Patent Application:
Test device for rapid diagnostics
Next Patent Application:
Baalc expression as a diagnostic marker for acute leukemia
Industry Class:
Chemistry: molecular biology and microbiology

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Affinity tag nucleic acid and protein compositions, and processes for using same patent info.
IP-related news and info

Results in 1.72097 seconds

Other interesting Feshpatents.com categories:
Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , paws

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO